Mao Pingping
Mao Pingping
Postdoc in Department of Medical Oncology, Dana Farber Cancer Institute
Подтвержден адрес электронной почты в домене dfci.harvard.edu
Название
Процитировано
Процитировано
Год
Serine/threonine kinase 17A is a novel p53 target gene and modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells
P Mao, MP Hever, LM Niemaszyk, JM Haghkerdar, EG Yanco, D Desai, ...
Journal of Biological Chemistry 286 (22), 19381-19391, 2011
792011
Serine/threonine kinase 17A is a novel candidate for therapeutic targeting in glioblastoma
P Mao, MP Hever-Jardine, GJ Rahme, E Yang, J Tam, A Kodali, B Biswal, ...
PLoS One 8 (11), e81803, 2013
572013
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor–positive metastatic breast cancer
SA Wander, O Cohen, X Gong, GN Johnson, JE Buendia-Buendia, ...
Cancer discovery 10 (8), 1174-1193, 2020
552020
Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer
P Mao, O Cohen, KJ Kowalski, JG Kusiel, JE Buendia-Buendia, ...
Clinical Cancer Research 26 (22), 5974-5989, 2020
302020
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer …
SA Wander, O Cohen, X Gong, GN Johnson, JE Buendia-Buendia, ...
CD-19-1390.[PubMed][CrossRef][Google Scholar], 0
14
Abstract PD4-01: The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER+ breast cancer
P Mao, J Kusiel, O Cohen, N Wagle
Cancer Research 78 (4 Supplement), PD4-01-PD4-01, 2018
112018
Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors …
SA Wander, O Cohen, GN Johnson, D Kim, F Luo, P Mao, U Nayar, ...
Journal of Clinical Oncology 36 (15_suppl), 12016-12016, 2018
102018
Headway and hurdles in the clinical development of dietary phytochemicals for cancer therapy and prevention: lessons learned from vitamin A derivatives
CY Yim, P Mao, MJ Spinella
The AAPS journal 16 (2), 281-288, 2014
72014
Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+ …
SA Wander, O Cohen, X Gong, GN Johnson, J Buendia-Buendia, M Lloyd, ...
Cancer Research 80 (4 Supplement), PD2-09-PD2-09, 2020
42020
Abstract PS5-10: Esr1 mutation as a potential predictor of abemaciclib benefit following prior cdk4/6 inhibitor (cdk4/6i) progression in hormone receptor-positive (hr+ …
SA Wander, HS Han, GN Johnson, MR Lloyd, P Mao, U Nayar, ...
Cancer Research 81 (4 Supplement), PS5-10-PS5-10, 2021
12021
Cell-line-specific network models of ER+ breast cancer identify PI3Kα inhibitor sensitivity factors and drug combinations
JGT Zañudo, P Mao, C Alcon, KJ Kowalski, GN Johnson, G Xu, J Baselga, ...
bioRxiv, 2020
12020
Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) using whole …
O Cohen, J Buendia-Buendia, S Wander, U Nayar, P Mao, A Waks, D Kim, ...
Cancer Research 79 (4 Supplement), PD9-02-PD9-02, 2019
12019
Abstract P3-03-08: A large-scale functional screen to identify resistance mechanisms to selective estrogen receptor degraders fulvestrant and GDC-810 in ER+ breast cancer
P Mao, Q Quartey, O Cohen, F Piccioni, N Wagle
Cancer Research 77 (4 Supplement), P3-03-08-P3-03-08, 2017
12017
STK17A is a potential therapeutic target in glioblastoma
P Mao, MP Jardine, GJ Rahme, EC Yang, J Tam, A Kodali, B Biswal, ...
Cancer Research 74 (19 Supplement), 4605-4605, 2014
12014
The novel protein kinase STK17A is a direct p53 target gene that mediates response to genotoxic and nutritional stress in a cancer cell context-dependent manner
P Mao, M Jardine, L Niemaszyk, J Haghkerdar, E Yang, D Desai, ...
Cancer Research 72 (8 Supplement), 2958-2958, 2012
12012
Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
JGT Zañudo, P Mao, C Alcon, K Kowalski, GN Johnson, G Xu, J Baselga, ...
Cancer Research 81 (17), 4603-4617, 2021
2021
Abstract PD7-08: Igf1r mediates cdk4/6 inhibitor (cdk4/6i) resistance in tumor samples and in cellular models
SA Wander, P Mao, MR Lloyd, GN Johnson, K Kowalski, U Nayar, ...
Cancer Research 81 (4 Supplement), PD7-08-PD7-08, 2021
2021
Esr1 mutation as a potential predictor of abemaciclib benefit following prior cdk4/6 inhibitor (cdk4/6i) progression in hormone receptor-positive (hr plus) metastatic breast …
SA Wander, HS Han, GN Johnson, MR Lloyd, P Mao, U Nayar, ...
CANCER RESEARCH 81 (4), 2021
2021
Abstract P6-10-08: AKT1 alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC): Clinical and …
S Wander, P Mao, M Lloyd, K Kowalski, GN Johnson, G Malvarosa, B Moy, ...
Cancer Research 80 (4 Supplement), P6-10-08-P6-10-08, 2020
2020
Abstract GS2-02: Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem …
O Cohen, P Mao, U Nayar, JE Buendia-Bue, D Kim, E Jain, K Helvie, ...
Cancer Research 80 (4 Supplement), GS2-02-GS2-02, 2020
2020
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20